# Immunologic Response to FluMist vs. Flucelvax

> **NCT03982069** · PHASE4 · COMPLETED · sponsor: **Richard Zimmerman MD** · enrollment: 465 (actual)

## Conditions studied

- Influenza, Human
- Immune Response

## Interventions

- **BIOLOGICAL:** FluMist live attenuated influenza vaccine
- **BIOLOGICAL:** Flucelvax inactivated influenza vaccine

## Key facts

- **NCT ID:** NCT03982069
- **Lead sponsor:** Richard Zimmerman MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-20
- **Primary completion:** 2020-12-09
- **Final completion:** 2020-12-09
- **Target enrollment:** 465 (ACTUAL)
- **Last updated:** 2021-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03982069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03982069, "Immunologic Response to FluMist vs. Flucelvax". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03982069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*